Clinical Trials Browser

Terminated × Brentuximab Vedotin × Clear all

Hodgkin Disease

NCT04254107 2025-02-10

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Triple Negative Breast Neoplasms

NCT03138499 2024-01-10

CheckMate 812

Phase 3 Terminated

23 enrolled 14 charts

Lymphoid

Hodgkin Disease

NCT03947255 2023-10-13

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Phase 2 Terminated

12 enrolled 17 charts

Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02499627 2021-05-27

FIL-BBV

Phase 2 Terminated

43 enrolled

Lymphoid

Lymphatic Diseases, Lymphoma

NCT02988843 2020-12-10

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Phase 2 Terminated

1 enrolled 8 charts

Neoplasms, Germ Cell and Embryonal

NCT02254239 2019-12-12

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Terminated

10 enrolled

Lymphoid

Hodgkin Disease

NCT02689219 2019-12-10

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Phase 2 Terminated

18 enrolled 13 charts

Genitourinary

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

NCT02169505 2019-11-27

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Phase 2 Terminated

2 enrolled 5 charts

Lymphoid

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Lymphoma, Large-Cell, Anaplastic

NCT01925612 2018-06-21

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Terminated

87 enrolled 18 charts

Lymphoid

Hematologic Diseases, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00354107 2018-03-14

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Phase 1/2 Terminated

5 enrolled 9 charts

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Phase NA Terminated

1 enrolled 5 charts

Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT00649584 2014-12-18

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Phase 1 Terminated

44 enrolled

Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

Phase 2 Terminated

6 enrolled 3 charts

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Clinical Trials

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

CheckMate 812

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

FIL-BBV

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma